Pipeline

Using its proprietary CAR platform, Leucid Bio has developed a pipeline of assets for the treatment of solid tumours and haematological malignancies.

Category

Programme

Preclinical 

IND Enabling

Phase I/II

Product

Solid Tumours

LEU-001
pan-ErbB

Autologous CAR T-cells
T4 (SCCHN)

LEU-011
NKG2DL

Autologous CAR T-cells
(PROC)

LEU-005

Allogeneic CAR T-cells

Haematological
Malignancies

LEU-004

LEU-006

Autologous CAR T-cells
 

Allogeneic CAR T-cells